RI-BPI has antilymphoma activity in vivo. (A) Tumor growth plots in SUDHL4 and SUDHL6 xenografted mice treated with control (●) or RI-BPI at 150 μg/day (□) or at 500 μg/day () for 10 consecutive days. The control peptide group includes mice treated with both the 150 and 500 μg/day doses, which were pooled to facilitate visualization. The y-axis represents the percentage of tumor volume (in mm³) compared to day 1 of treatment and x-axis represents treatment day. (B) Tumor burden (in milligrams) at day 10 in control (■), RI-BPI 150 μg/day (□), and RI-BPI 500 μg/day () treated SUDHL4 and SUDHL6 mice. (C) Serum levels of human β₂-microglobulin (measured in micrograms per milliliter and expressed as percentage to their respective controls) at day 10 in control (■), RI-BPI 150 μg/day (□), and RI-BPI 500 μg/day () treated SUDHL4 and SUDHL6 mice. (D) Kaplan-Meier survival curves for the pooled mice treated with control (dashed black line), 150 μg/day (gray line), and RI-BPI 500 μg/day (black line). A positive event was defined preanalysis as either death of the animal or tumor equal to 10 times the initial volume, whichever occurs first.